Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte (INCY) PT Lowered to $92 at RBC Capital Following Earnings
May 4, 2021 12:51 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $92.00 (from $93.00) while maintaining a Sector Perform rating following reults.
The analyst commented, "A soft quarter for INCY from combined pandemic/seasonal oncology headwinds, though signs suggest to us... More
Incyte (INCY) Tops Q1 EPS by 4c
May 4, 2021 7:18 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of $0.67, $0.04 better than the analyst estimate of $0.63. Revenue for the quarter came in at $605 million versus the consensus estimate of $656.88 million.
2021... More
